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PDGFRA and c-KIT are two related receptor tyrosine kinases showing similar structure, and mutations of these genes are detected in gastrointestinal stromal tumor 2, 3 and myeloproliferative disorders. 4 Recently, we reported a PDGFRA N870S mutation in a 13-year-old boy having acute myelogenous leukemia (AML)-M1 with t(8;21) and an F808L mutation in a 13-year-old girl having AML-M1 with inv(16). 5 In addition to point mutations, the FIP1L1-PDGFRA fusion tyrosine kinase resulting from internal deletion of 4q12 locus was described in a subgroup of patients presenting hypereosinophilic syndrome. 6 Here, we investigated whether PDGFRA is also implicated in the pathogenesis of acute lymphoblastic leukemia (ALL), and found a mutation which renders a factor-dependent cell line factorindependent by its aberrant tyrosine phosphorylation.
One hundred and twenty seven childhood ALL and 40 infant ALL samples, including those from 13 patients with t(4;11)(q21;q23) (one patient was childhood ALL and the others were infant ALL), were analyzed for the expression and mutation of PDGFRA. PDGFRA gene was expressed in 38 (29.9%) of the 127 childhood ALL patient samples, 12 (30.0%) of the 40 infant ALL patients and 9 (36.0%) of the 25 ALL patients associated with MLL gene rearrangements. Sequence analyses of the samples expressing PDGFRA revealed a PDGFRA A509D mutation ( Figure 1a ) in a 4-month-old boy having ALL with t(4;11)(q21;q23). This mutation in the Ig5 domain of PDGFRA corresponds to those responsible for ligand-independent kinase activation of c-KIT in gastrointestinal stromal tumor. 3 Mutations on exon 9 encoding the extracellular domain near the transmembrane domain of c-KIT lead to ligandindependent activation of c-KIT, 2, 3 and are associated with core binding factor AML and gastrointestinal stromal tumor. 1, 3, 7 We examined whether the mutation at Ig5 domain of the PDGFRA gene resulted in constitutive activation of the kinase activity by retroviral transduction 8 of the wild-type and mutated PDGFRA cDNAs into an IL-3 dependent mouse cell line, Ba/F3 and stable cell lines expressing each transgene were established. The whole coding region of PDGFRA cDNA was sequenced directly or after subcloning into a retroviral vector pMXs-IN(IRES-Neo). 8 The empty vector as a negative control was also introduced into Ba/F3 cells. As expected, the wild-type PDGFRA was not significantly phosphorylated on tyrosine residues in the absence of PDGF (Figure 1b ). In contrast, the PDGFRA with the Ig5 domain A509D mutation was phosphorylated in the absence of PDGF (Figure 1b ). Because the signal transduction pathway of PDGFRA is comparable with that of c-KIT, 2 the gain-of-function mutations of PDGFRA by themselves may transform Ba/F3 cells. In fact, Ba/F3 cells expressing the A509D mutant PDGFRA grew in the absence of IL-3 and PDGF whereas those expressing the wild-type did not (data not shown). It is possible that the mutant PDGFRA may contribute to leukemogenesis with t(4;11).
In conclusion, we reported the frequency of PDGFRA mutations in a large series of Japanese pediatric and infantile ALL patients. This is the first report showing a constitutively active PDGFRA mutation found in an ALL patient that may be associated with leukemic cell growth. 
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Letters to the Editor
Primary genetic abnormalities in myeloma (MM) such as trisomies of chromosomes 3, 5, 7, 9, 11, 15, 19 and 21 associated with hyperdiploid MM and translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 and three main recurrent partners: MMSET/FGFR3, CCND1 and c-MAF are already present in the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) stage.
1 Some patients with these genetic abnormalities may remain as MGUS for many years without transforming to MM, suggesting that they are involved in clonal initiation but do not mediate malignant transformation.
One of the recurrent differences between MGUS and MM is the presence of RAS mutations in the latter. RAS mutations may, therefore, play an important role in malignant transformation of clonal plasma cells and myeloma pathogenesis. However, the clinical and biological significance of RAS mutation in MM has not been clearly established as most of the previous studies have involved small numbers of heterogeneously treated patients.
To establish the clinical and biological significance of RAS mutation in MM, we studied the association of RAS mutation with a comprehensive spectrum of clinical parameters including the newly established ISS staging and survival, as well as a panel of known recurrent genetic abnormalities in MM such as t(4;14), t(14;16), t(11;14), chromosome 13 and 17p13 deletion detected by fluorescent in situ hybridization 2 and ploidy assessed by DNA content measurement using flow cytometry, 3 in a large cohort of newly diagnosed patients enrolled in the Eastern Cooperative Group (ECOG) clinical trial E9486/E9487 (N ¼ 561). 4 A total of 439 patients, based on sample availability, were included (The ECOG Cohort). For this cohort, DNA from unsorted whole bone marrow was used for RAS mutation studies. We also studied 14 MGUS patients and 82 MM patients (60 newly diagnosed and 22 relapsed) from the Mayo Clinic (Mayo Cohort). Bone marrow samples were obtained after informed consent according to the Declaration of Helsinki. The study was approved by the Mayo Clinic Institution Review Board. CD138 positive plasma cells were enriched using immuno-magnetic beads (AutoMACS; Miltenyi-Biotec, Auburn, CA, USA). RNA and DNA from these enriched cells were used for gene expression and RAS mutation studies, respectively.
Conformation sensitive gel electrophoresis was used to screen samples for KRAS (codons 12, 13 and 61) and NRAS (codons 12, 13 and 61) mutations (Supplementary Methods). RAS mutation was detected in 102 (23%) patients in the ECOG cohort. Seventy-four (17%) patients had mutations in NRAS. The majority of these mutations were in codon 61 (64 of the 74), with 5 mutations detected in codons 12 and 13. We also found mutations in codon 64 (n ¼ 1) and codon 86 (n ¼ 4). Twentyeight (6%) patients had mutations in K-RAS. Twenty-two of these are in codons 12 and 13 and three in codon 61. In addition, we also found one mutation each in codon 16, 22 and 24. In the Mayo Clinic cohort, RAS mutation was detected in 1 of 14 MGUS patients (7%), 15 of 60 newly diagnosed MM patients (25%) and 10 of 22 relapsed MM patients (45%). Once again N-RAS mutations were more common that K-RAS mutations. Our study confirms the low incidence of RAS mutation in MGUS compared to MM found in a previous study, 5 consistent with
